A Phase 1 Study of BLU-285 in Patients with Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies
There are 2 parts to this study: Part 1 (dose escalation) and Part 2 (dose expansion). The goal of Part 1 of this clinical research study is to find the highest tolerable dose of avapritinib when given to patients with advanced systemic mastocytosis (AdvSM) or relapsed (has come back) or refractory (has not responded to treatment) myeloid malignancies. Part 1 of the study is now closed. The goal of Part 2 of this study is to compare the safety and tolerability of 2 dose levels of avapritinib in patients with AdvSM or relapsed or refractory myeloid malignancies. This is one of the first trials using avapritinib in humans.
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: BLU-285
Treatment Location: Both at MDACC & and Other Sites
Sponsor: Blueprint Medicines Corp.
IRB Review and Approval Date: 03/31/2016
Recruitment Status: Open
Projected Accrual: 80
Information and next steps
Malignant neoplasms stated as primary lymphoid haematopoietic
For general questions about clinical trials: